List your company

ResearchFormerly WizWand

Pathology report generation

Benchmarks

DatasetSOTA methodMetricTrendResultsLast updated

PathText BRCA (test)

0.46BLEU-1

32

Mar 5, 2026

REG 2025 (test Phase 2)

0.849Overall Score

15

Feb 26, 2026

ML-Path Mean (test)

0.273BLEU

9

Jul 2, 2026

ML-Path DLBC (test)

23BLEU Score

9

Jul 2, 2026

ML-Path CHOL (test)

21.3BLEU Score

9

Jul 2, 2026

ML-Path ACC (test)

22.2BLEU

9

Jul 2, 2026

ML-Path MESO (test)

20.3BLEU

9

Jul 2, 2026

ML-Path LIHC (test)

24.7BLEU Score

9

Jul 2, 2026

ML-Path STAD (test)

0.279BLEU Score (Mean)

9

Jul 2, 2026

ML-Path COAD (test)

0.259BLEU Score (Mean)

9

Jul 2, 2026

ML-Path THCA (test)

0.286BLEU

9

Jul 2, 2026

ML-Path KIDNEY (test)

32.4BLEU Score (Mean)

9

Jul 2, 2026

ML-Path LUNG (test)

26.9BLEU Score

9

Jul 2, 2026

ML-Path BRCA (test)

25BLEU Score

9

Jul 2, 2026

Multi-organ pathology dataset (test)

0.551BLEU-1

9

Feb 26, 2026

Stage 2 baseline

460Ours Favored Count

3

Jun 1, 2026

HistGen overlapping skin cases subset of 67

0.85Diagnostic Consistency (mean/3)

2

Jun 1, 2026

Melanocytic Lesion Reader Study Other lesions, N=25 (test)

—

—Primary metric

0

Feb 26, 2026

Melanocytic Lesion Reader Study Common nevi N=25 (test)

—

—Primary metric

0

Feb 26, 2026

Melanocytic Lesion Reader Study All cases, N=50 (test)

—

—Primary metric

0

Feb 26, 2026